CLConsumer Defensive · Household & Personal ProductsThe 21 Wall Street analysts covering Colgate-Palmolive Co. hold a median 12-month price target of $100 — +7.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Colgate-Palmolive Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Growth (45): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.8% from it.
Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $95 → $90 |
| 21 Sept 2026 | Piper Sandler | Maintains | Overweight | — |
| 21 Sept 2026 | Piper Sandler | Maintains | Overweight | $98 → $95 |
| 8 Sept 2026 | RBC Capital | Reiterates | Outperform | $104 |
| 8 Sept 2026 | RBC Capital | Reiterates | Outperform | — |
| 3 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 3 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $100 → $101 |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | $104 → $103 |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 3 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 3 Aug 2026 | RBC Capital | Maintains | Outperform | $102 → $104 |
| 3 Aug 2026 | TD Cowen | Maintains | Hold | — |
| 3 Aug 2026 | TD Cowen | Maintains | Hold | $85 → $90 |
| 3 Aug 2026 | UBS | Maintains | Buy | — |
| 3 Aug 2026 | UBS | Maintains | Buy | $106 → $109 |
| 21 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 21 July 2026 | Barclays | Maintains | Equal-Weight | $80 → $87 |
| 16 July 2026 | JP Morgan | Maintains | Overweight | — |
| 16 July 2026 | JP Morgan | Maintains | Overweight | $96 → $104 |
| 16 July 2026 | UBS | Maintains | Buy | $100 → $106 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Colgate-Palmolive Co. returned +21.3% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 35% of US stocks
Cheaper than 1% of US stocks
Cheaper than 21% of US stocks
Higher than 39% of US stocks
Higher than 29% of US stocks
Higher than 75% of US stocks
Higher than 80% of US stocks
Higher than 69% of US stocks
Higher than 99% of US stocks
Higher than 98% of US stocks
Higher than 81% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Colgate-Palmolive Co. has a market value of $71.7B and an enterprise value of $78.5B.
Revenue in the twelve months to 30 June 2026: $21.0B. The latest quarter grew 4.9% year on year.
Net income over the same four quarters: $2.2B, a 10.3% net margin.
Diluted earnings per share, trailing twelve months: $2.52.
Free cash flow in the twelve months to 30 June 2026: $3.9B, after $598.0M of capital spending.
Colgate-Palmolive Co. spent $1.3B on share buybacks and $1.8B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 35.4×; forward P/E: 22.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.36%, paying out 82% of earnings.
Colgate-Palmolive Co. employs 33,600 people — $626K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Colgate-Palmolive Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The comparison says Colgate-Palmolive’s fundamentals are supported by global diversification, emerging-market growth and Hill’s strength, while Clorox relies on recovery and GOJO.
Why it matters — CL watchers may note the factors highlighted as supporting Colgate-Palmolive in the comparison with Clorox.
Zacks Investment Research highlights that Colgate-Palmolive's innovation, premiumization strategy, and expansion in emerging markets are strengthening its brands and creating avenues for long-term growth. The piece questions whether this momentum can be sustained going forward.
Why it matters — A CL watcher would care because the article points to the strategic drivers underpinning the company's growth prospects.
Zacks Investment Research published an article examining National Vision (EYE) and Colgate-Palmolive (CL), both in the Consumer Products - Staples sector, to assess which may be the better value stock for investors seeking undervalued opportunities. The piece directly compares the two companies on that valuation basis.
Why it matters — A CL watcher would care because the article evaluates whether Colgate-Palmolive represents a comparatively undervalued pick among consumer staples names.
24/7 Wall Street examines Colgate-Palmolive's uninterrupted dividend streak dating back to 1895, while noting that the company's shrinking North American business now conflicts with its premium valuation, which leaves little room for error.
Why it matters — A CL watcher would care because the piece highlights a tension between the company's long dividend history and current pressures on its North American business and valuation.
Zacks Investment Research, using its Style Scores system, identifies Colgate-Palmolive (CL) as a strong growth stock. The article describes the Style Scores framework as a way for investors to find top-rated stocks based on their investing style.
Why it matters — CL watchers would care because the item indicates that Colgate-Palmolive ranks well under Zacks' growth-focused stock scoring methodology.
The 21 Wall Street analysts covering Colgate-Palmolive Co. have a median 12-month price target of $100, with estimates ranging from $87 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering Colgate-Palmolive Co., 13 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Colgate-Palmolive Co. 93 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Colgate-Palmolive Co. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +7.8% from the last close, and Ticker Nerd's factor model ranks Colgate-Palmolive Co. 93 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Colgate-Palmolive Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $87 to $110 over the next 12 months.
Colgate-Palmolive Co. returned +21.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Colgate-Palmolive Co. is a global consumer products company focused on oral care, personal care, home care, and pet nutrition.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Colgate vs. Clorox: Which Consumer Staples Giant Holds the Edge?". The comparison says Colgate-Palmolive’s fundamentals are supported by global diversification, emerging-market growth and Hill’s strength, while Clorox relies on recovery and GOJO.
Colgate-Palmolive Co. is a global consumer products company focused on oral care, personal care, home care, and pet nutrition. Its portfolio includes well-known brands such as Colgate, Palmolive, Softsoap, Speed Stick, Fabuloso, and Hill’s Science Diet, serving everyday household, hygiene, and pet care needs. The company sells through traditional retail, e-commerce, wholesale, dental, skin health, and veterinary channels across markets worldwide. Colgate-Palmolive Co. plays a significant role in the consumer staples sector by supplying essential products used regularly by households, professionals, and pet owners in many regions.
CEO Mr. Noel R. Wallace · 33,600 employees · United States · https://www.colgatepalmolive.com
